Swallowing development in infants and toddlers with spinal muscular atrophy following therapy compared to healthy controls: the prospective controlled DySMA trial
Authors:
Open Access
- 16 February 2026
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Abstract
Background: Swallowing development is a crucial outcome measure for evaluating the effectiveness of disease-modifying therapies (DMT) in children with spinal muscular atrophy (SMA). However, data on this aspect remain limited due to a lack of assessment tools. This study aimed to evaluate swallowing development in infants and toddlers with SMA, compare it with healthy controls (HC), and investigate the influence of initial symptom status at start of DMT and SMN2 copy number. Methods: An observational study was conducted with infants and toddlers diagnosed with SMA at a single neuropediatric center and a HC group. Swallowing development was primarily assessed using the DySMA scale. Group differences and the impact of initial symptom status and SMN2 copy number on swallowing were analyzed using linear mixed-effects models. Results: The study included 127 infants and toddlers, 35 with SMA (0–36 months, 19 girls), who started DMT either presymptomatically ( n = 18) or symptomatically ( n = 17), with two ( n = 26) or three ( n = 9) SMN2 copies, predominantly receiving Onasemnogene abeparvovec alone ( n = 26), and a healthy control group ( n = 92, 0–23 months, 34 girls). Children with SMA displayed significantly different swallowing development trajectories (-0.06 DySMA points by months of life, p =.06; 95% CI -0.13 to 0.01) compared to HC (+ 0.45 DySMA points by months of life, p <.01, 95% CI 0.25 to 0.65). Notably, those treated presymptomatically demonstrated swallowing progress comparable to HC up to 15–17 months but experienced a decline thereafter (18–24 months; β = 8.22, p <.001; 95% CI 4.20 to 12.26). The group with three SMN2 copies exhibited a developmental pattern similar to HC up to the age of 24 months. Conclusion: Higher SMN2 copy number and presymptomatic DMT initiation were associated with similar early swallowing development compared to HC. Long-term studies stratifying swallowing development by SMN2 copy number are warranted.Keywords
Funding Information
- Universitätsklinikum Hamburg-Eppendorf (UKE)
This publication has 32 references indexed in Scilit:
- Feeding development in healthy infants: A comparative framework for children with Spinal Muscular Atrophy – The DySMAnorm studyInternational Journal of Pediatric Otorhinolaryngology, 2025
- Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational studyThe Lancet Regional Health - Europe, 2024
- Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic reviewMuscle & Nerve, 2024
- Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapiesPediatric Pulmonology, 2024
- Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudyMuscle & Nerve, 2023
- Flexible endoscopic evaluation of swallowing in children with type 1 spinal muscular atrophyEuropean Archives of Oto-Rhino-Laryngology, 2022
- Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screeningEuropean Journal of Pediatrics, 2022
- Trajectory of change in the swallowing status in spinal muscular atrophy type IInternational Journal of Pediatric Otorhinolaryngology, 2020
- Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotypeHuman Genetics, 2019
- Feeding problems and malnutrition in spinal muscular atrophy type IINeuromuscular Disorders, 2008